Richard Peters is the founder of Yumanity Therapeutics. Yumanity Therapeutics has raised $45M in total funding. Latest round: Series A.
Richard Peters is the CEO of Yumanity Therapeutics, an early-stage biotech focused on neurodegeneration, having taken the role after previously serving as CEO of Merrimack Pharmaceuticals. He leads the company as it advances programs in preclinical and early clinical stages.
Full founder directory · Investor directory · Company funding database · Fundraising library